Company: PRTA
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001559053-25-000031
Chunk: 43

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 2
Chunk 43
---
 unless each agreement is cancelled by us. We do not consider the renewals in the lease term as we do not believe it to be reasonably certain that we will renew these leases, as our real estate needs are subject to change based on our business needs.

In October 2022, we entered into a noncancelable operating sublease to lease approximately 31,157 square feet of office and laboratory space in Brisbane, California. We are obligated to make lease payments totaling approximately $14.9 million over the lease term, which expires onSeptember 30, 2028, unless terminated earlier. Of this obligation, approximately $10.5 million remains outstanding as of June 30, 2025

The following is a summary of our contractual obligations as ofJune 30, 2025(in thousands):

                                                        Total                  2025                  2026      2027      2028  
  Operating leases (1)                                  $          10,771      $          1,678      $         $         $     
  Purchase obligations (2)                                          3,339                 3,216      123       —         —     
  Obligations under the restructuring plan (3)                     30,330                30,039      291       —         —     
  Contractual obligations under license agreements      309                    59                    70        70        55    
  Total                                                 $          44,749      $         34,992      $         $         $     

(1)See Note 6,“ Commitments and Contingencies” to our Condensed Consolidated Financial Statements.

(2) As of the filing date, there were no material changes to our Purchase obligations subsequent to June 30, 2025.

(3) Includes cash obligations under our restructuring plan. For additional information, see Note 11, “ Restructuring” to our Condensed Consolidated Financial Statements.

In addition to the contractual obligations above, we also expect to have future material cash requirements related to our clinical trials, discovery and pre-clinical programs, human capital and intellectual property. Assuming no significant change in our business, we expect the full year 2025 net cash used in operating and investing activities to be approximately $170 million to $178 million.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK